600085.SH plans to acquire 60% of Tianjin Tongren Tang's shares for 2,444 billion yuan

Zhitong Finance App News, Tong Ren Tang (600085.SH) announced that the company plans to acquire 60% of the shares of Tianjin Tongrentang Group Co., Ltd. (Tianjin Tongrentang for short) held by China Beijing Tongrentang (Group) Co., Ltd. (Tongren Group for short) for 2,444 billion yuan in cash.

The transaction is in line with the company's overall strategic plan and is conducive to achieving epitaxial growth in the company's business layout and mergers and acquisitions. Through the acquisition of Tianjin Tong Ren Tang, the company's product line can be enriched. In addition to receiving assets related to Tianjin Tongrentang, Tianjin Tongrentang's core products, such as nephritis rehabilitation tablets, Xuefu Chuyu capsules, and vascular rehabilitation tablets, are mainly sold by public medical institutions, and have accumulated a mature academic promotion system and terminal resources through in-hospital channels. The company's sales system is centered on out-of-hospital retail. Large single products such as Angong beef yellow pills have significant brand advantages in the OTC market. There are obvious differences in channel structures between the two sides, and the complementarity is strong. The synergy of existing marketing resources and cost advantages between the two sides will have a positive impact on the company.